How do people get peptides? Prescription, compounded and research-grade channels explained

The legal way to get a peptide medicine runs through a licensed prescriber: an approved drug, a limited compounded drug, a clinical trial or expanded access.

Basics7 min read

Key takeaway

There are four legal routes to a peptide medicine. They are an FDA-approved product on prescription, a limited compounded drug, a clinical trial or expanded access. Each one involves a licensed clinician. A fifth channel, research-grade material, is for laboratory research use only, not for human or veterinary use. FDA has warned sellers that marketed research-labeled peptides to consumers for human use.

At a glance

Article typeBasics
TopicLaw & regulation
Studies cited0
Related productsResearch peptide catalog

The legal way to get peptides for your own health runs through a licensed prescriber. FDA-approved peptide medicines need a prescription and a state-licensed pharmacy. Compounded versions are allowed only in limited cases. Drugs that are not approved yet are reached through clinical trials or expanded access. Research-grade peptides are laboratory reagents, not a personal-use option. Sources were checked on November 17, 2026.

Quick answer: Start with a licensed clinician. If an FDA-approved peptide medicine fits your condition, it comes with a prescription from a state-licensed pharmacy. Compounding is narrow and is not FDA approval. Unapproved drugs are reached only through registered trials or expanded access. We do not recommend any compound, and research-grade peptides are never a substitute for medical care.

This article summarizes public regulatory records. It is not legal or medical advice.

People who search for peptides usually want help with a health goal, such as weight, healing or energy. That goal is worth taking to a clinician. Table 1 shows the routes that exist in US law and what each one requires.

Table 1

Routes to a peptide medicine in the United States (checked November 17, 2026)

Route What it is What the law requires
FDA-approved medicine A product FDA reviewed, with an official label A prescription, filled at a state-licensed pharmacy
Compounded drug A drug made by a pharmacy or registered outsourcing facility Section 503A or 503B conditions; not FDA-approved
Clinical trial A registered study of an investigational drug Eligibility, informed consent and ethics board review
Expanded access Use of an investigational drug outside a trial Serious condition, physician request, company agreement, FDA review
Research-grade material A laboratory reagent For laboratory research use only; not a route to personal use

How does the prescription route work?

FDA has approved many peptide medicines, from oxytocin to semaglutide and tirzepatide. Our list of FDA-approved peptide medicines shows each one, its brand and its approved use. Drugs@FDA records each product's marketing status, and the active products on that list are prescription medicines (Drugs@FDA).

FDA's advice is plain: "Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy" (FDA, 2026). The prescriber chooses the product and sets the dose from its label.

When is a compounded peptide legal?

FDA states that "compounded drugs are not FDA-approved" and that it does not verify their safety, effectiveness or quality before they are sold. It says they "should only be used in patients whose medical needs cannot be met by an FDA-approved drug" (FDA, 2025).

A 503A pharmacy may use a bulk ingredient only if it passes one of three tests. It must have a USP or NF monograph, be in an FDA-approved drug, or be on the 503A bulks list (FDA, 2026). Few peptides fit those tests today.

  • Semaglutide and tirzepatide. FDA says they "do not currently appear on the 503B bulks list or on FDA's drug shortage list" (FDA, 2026).
  • Retatrutide. FDA states that "Retatrutide and cagrilintide cannot be used in compounding under federal law" (FDA, 2026).
  • BPC-157 and 16 others. FDA lists them as nominated but withdrawn, "previously in category 2," its significant-safety-risk group (FDA, 2026).
  • The HHS draft policy. On October 30, 2026, HHS said it does not intend to take enforcement action against 503A compounders using peptides in its Appendix A. The notice says it "is not binding on HHS or the public" (HHS, 2026).

Our guides to 503A and 503B compounding and peptides and the FDA in 2026 cover these rules in detail.

Can research-grade peptides be used instead?

No. Research-grade peptides are laboratory reagents, sold for laboratory research use only, not for human or veterinary use. They have no FDA label, no prescriber and no pharmacy behind them.

A label does not settle the legal question either. FDA judges intended use by the seller's "objective intent," shown by labeling, advertising and how a product is sold (21 CFR 201.128). FDA has warned companies that sold research-labeled GLP-1 products directly to consumers for human use, with dosing instructions. FDA urges consumers not to buy them. It calls them "of unknown quality" and says they "may be harmful" (FDA, 2026). See FDA warning letters to peptide sellers and the risks of using research peptides on yourself.

How do people get a peptide drug that is not approved yet?

Only through the company developing it, inside the rules. A registered clinical trial is the main route. For people with a serious condition who cannot join a trial, expanded access may be possible. FDA says a licensed physician makes the request, the company must agree, and FDA decides whether it may proceed (FDA, 2026).

Retatrutide shows how this works. In June 2026, Eli Lilly listed a single-patient expanded access program for adults with severe obesity who cannot join a trial (NCT07629401). Our guide on how to find a peptide clinical trial walks through both routes.

How do you talk to a clinician about peptides?

You do not need the right vocabulary. A good visit starts with your goal, not with a product name. These steps help.

  • Bring your health picture. List your conditions, medicines and supplements, and any product you have already used.
  • Name what you read about. Say where you saw it. A clinician can tell you whether it is an approved medicine, a compounded drug or neither.
  • Ask the core questions. The federal Agency for Healthcare Research and Quality suggests asking "Why do I need this treatment?", "Are there any alternatives?" and "Are there any side effects?" (AHRQ, 2020).
  • Ask about interactions. AHRQ also suggests: "Will this medicine interact with medicines that I'm already taking?"
  • Ask about the source. Is the product FDA-approved for your condition? If it is compounded, which pharmacy makes it?

If you are weighing a clinic or telehealth service, our guide to what peptide therapy is lists questions to ask before you pay.

What are the red flags when buying peptides online?

FDA's BeSafeRx program and its GLP-1 safety page list warning signs. A seller may be unsafe if it:

  • does not require a prescription, or a screening by a licensed doctor;
  • is not licensed by your state board of pharmacy;
  • offers "deep discounts or prices that seem too good to be true";
  • claims a compounded drug is the same as an FDA-approved drug;
  • sends medicine that looks different from what your local pharmacy dispenses;
  • sells "research use only" products with directions for people to use them.

FDA's state-licensed pharmacy lookup links each state's license database. FDA says that if your online pharmacy is not listed there, you should not use it. Our page on counterfeit GLP-1 medicines covers fake pens and illegal pharmacies.

Where can you get help or report a problem?

  • A licensed clinician or pharmacist for any question about a medicine you take or are considering.
  • FDA MedWatch to report a side effect or a product problem, online through MedWatch or by calling 1-888-INFO-FDA (1-888-463-6332) and pressing 2.
  • Poison Help at 1-800-222-1222 or poison.org after a possible poisoning. Call 911 in an emergency.

Frequently asked questions about getting peptides legally

How do you get peptides?

Legally, through a licensed prescriber. FDA-approved peptide medicines need a prescription filled at a state-licensed pharmacy, and unapproved drugs are reached only through clinical trials or expanded access. Research-grade peptides are for laboratory research use only.

Where can I get peptides for weight loss?

Wegovy (semaglutide), Zepbound (tirzepatide) and Saxenda (liraglutide) are FDA-approved prescription medicines for long-term weight management in eligible patients. A licensed clinician decides whether one fits you. Research-grade vials are not weight-loss products.

What peptides should I take?

We cannot answer that, and no website should. Only a licensed clinician who knows your health can say whether any medicine fits you. Our list of FDA-approved peptide medicines shows what exists and what each is approved for.

Can my doctor prescribe BPC-157?

Not as an approved drug, because BPC-157 has no FDA approval for any use. As of November 17, 2026, it is also not on the 503A bulks list. FDA has posted no final decision after its July 2026 advisory committee review.

How do I talk to my doctor about peptides?

Start with your health goal, then list your conditions, medicines and supplements and name any product you have read about. Ask whether it is FDA-approved for your condition, what the alternatives are and what side effects to expect.

What to know now

  • Start with a clinician: every legal route to a peptide medicine involves one.
  • Approved medicines: prescription only, filled at a state-licensed pharmacy.
  • Compounded drugs: not FDA-approved; limited to needs an approved drug cannot meet.
  • Unapproved drugs: clinical trials or expanded access, through the company and a physician.
  • Research grade: laboratory reagents, not for human or veterinary use.
  • Red flags: no prescription, no state license, prices too good to be true.

What we're watching

A final HHS peptide compounding policy. Any FDA decision on the peptides discussed in July 2026. New FDA action against sellers of peptides for human use.

Also in the library

Sources: U.S. Food and Drug Administration 2026, FDA's concerns with unapproved GLP-1 drugs used for weight loss; U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs . https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm, Drugs@FDA: FDA-approved drugs; U.S. Food and Drug Administration 2025, Compounding and the FDA: Questions and answers; U.S. Food and Drug Administration 2026, Bulk drug substances used in compounding under section 503A of the FD&C Act; U.S. Food and Drug Administration 2026, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize; U.S. Food and Drug Administration 2026; U.S. Department of Health and Human Services 2026; Electronic Code of Federal Regulations. 21 CFR 201.128: Meaning of "intended uses" . https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-E/section-201.128, 21 CFR 201.128: Meaning of "intended uses"; Electronic Code of Federal Regulations. 21 CFR 216.23: Bulk drug substances that can be used to compound drug products in accordance with section 503A . https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23; U.S. Food and Drug Administration 2026, July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee; U.S. Food and Drug Administration 2026, Expanded access: Information for patients; ClinicalTrials.gov 2026, Pre-approval expanded access of retatrutide (LY3437943); Agency for Healthcare Research and Quality 2020, The 10 questions you should know; U.S. Food and Drug Administration 2020, BeSafeRx: Considering an online pharmacy?; U.S. Food and Drug Administration 2024, Locate a state-licensed online pharmacy; National Library of Medicine. DailyMed labels: Wegovy, DailyMed labels: Wegovy, Zepbound and Saxenda; U.S. Food and Drug Administration 2025, Reporting serious problems to FDA (MedWatch); Poison Control, Poison Help line, 1-800-222-1222. All 18 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  2. U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
  3. U.S. Food and Drug Administration. (2025). Compounding and the FDA: Questions and answers (content current as of September 16, 2025). https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  4. U.S. Food and Drug Administration. (2026). Bulk drug substances used in compounding under section 503A of the FD&C Act (content current as of May 14, 2026). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  5. U.S. Food and Drug Administration. (2026). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of April 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  6. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  7. U.S. Department of Health and Human Services. (2026, October 30). Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. 91 FR 68526, document 2026-22192. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  8. Electronic Code of Federal Regulations. 21 CFR 201.128: Meaning of "intended uses". https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-E/section-201.128
  9. Electronic Code of Federal Regulations. 21 CFR 216.23: Bulk drug substances that can be used to compound drug products in accordance with section 503A. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23
  10. U.S. Food and Drug Administration. (2026). July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of August 6, 2026). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  11. U.S. Food and Drug Administration. (2026). Expanded access: Information for patients (content current as of October 29, 2026). https://www.fda.gov/news-events/expanded-access/expanded-access-information-patients
  12. ClinicalTrials.gov. (2026). Pre-approval expanded access of retatrutide (LY3437943), NCT07629401. https://clinicaltrials.gov/study/NCT07629401
  13. Agency for Healthcare Research and Quality. (2020). The 10 questions you should know. https://www.ahrq.gov/questions/10questions.html
  14. U.S. Food and Drug Administration. (2020). BeSafeRx: Considering an online pharmacy? https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/considering-online-pharmacy
  15. U.S. Food and Drug Administration. (2024). Locate a state-licensed online pharmacy. https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy
  16. National Library of Medicine. DailyMed labels: Wegovy, Zepbound and Saxenda. Wegovy; Zepbound; Saxenda
  17. U.S. Food and Drug Administration. (2025). Reporting serious problems to FDA (MedWatch). https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda
  18. Poison Control, National Capital Poison Center. Poison Help line, 1-800-222-1222. https://www.poison.org/